Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 28, 2009

Novartis Offers 28% More for Increased Control over India Operations

  • Novartis is upping its offer to acquire an additional stake in Novartis India by about 28%, bringing the value of the deal up to Rs. 5.64 billion, or roughly $118.48 million. Novartis says this is its final proposal.

    If the transaction goes through, Novartis would enjoy more control over Novartis India and would decrease dividends paid to minority shareholders in the subsidiary.

    Shares of Novartis India surged 20% to reach Rs. 467.50 in morning trading on the Bombay Stock Exchange. The firm is now trading over the current acquisition price being offered of Rs. 450 per share.

    In March Novartis sought to buy an additional 39% of its Indian subsidiary for Rs. 351 per share. The company currently owns 50.9% of Novartis India.

    Today’s offer comes at Rs. 450 per share, a 63% premium to the closing share price of Rs. 275.6 the day before the initial proposal was made.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »